Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets. 2017

Gale E Smith, and Xiangjie Sun, and Yaohui Bai, and Ye V Liu, and Michael J Massare, and Melissa B Pearce, and Jessica A Belser, and Taronna R Maines, and Hannah M Creager, and Gregory M Glenn, and David Flyer, and Peter Pushko, and Min Z Levine, and Terrence M Tumpey
Novavax, Inc., 20 Firstfield, Gaithersburg, MD 20878, USA.

Avian influenza A (H5N1) viruses represent a growing threat for an influenza pandemic. The presence of widespread avian influenza virus infections further emphasizes the need for vaccine strategies for control of pre-pandemic H5N1 and other avian influenza subtypes. Influenza neuraminidase (NA) vaccines represent a potential strategy for improving vaccines against avian influenza H5N1 viruses. To evaluate a strategy for NA vaccination, we generated a recombinant influenza virus-like particle (VLP) vaccine comprised of the NA protein of A/Indonesia/05/2005 (H5N1) virus. Ferrets vaccinated with influenza N1 NA VLPs elicited high-titer serum NA-inhibition (NI) antibody titers and were protected from lethal challenge with A/Indonesia/05/2005 virus. Moreover, N1-immune ferrets shed less infectious virus than similarly challenged control animals. In contrast, ferrets administered control N2 NA VLPs were not protected against H5N1 virus challenge. These results provide support for continued development of NA-based vaccines against influenza H5N1 viruses.

UI MeSH Term Description Entries
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D009439 Neuraminidase An enzyme that catalyzes the hydrolysis of alpha-2,3, alpha-2,6-, and alpha-2,8-glycosidic linkages (at a decreasing rate, respectively) of terminal sialic residues in oligosaccharides, glycoproteins, glycolipids, colominic acid, and synthetic substrate. (From Enzyme Nomenclature, 1992) Sialidase,Exo-alpha-Sialidase,N-Acylneuraminate Glycohydrolases,Oligosaccharide Sialidase,Exo alpha Sialidase,Glycohydrolases, N-Acylneuraminate,N Acylneuraminate Glycohydrolases,Sialidase, Oligosaccharide
D009976 Orthomyxoviridae Infections Virus diseases caused by the ORTHOMYXOVIRIDAE. Orthomyxovirus Infections,Infections, Orthomyxoviridae,Infections, Orthomyxovirus,Swine Influenza,Infection, Orthomyxoviridae,Infection, Orthomyxovirus,Influenza, Swine,Orthomyxoviridae Infection,Orthomyxovirus Infection
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005289 Ferrets Semidomesticated variety of European polecat much used for hunting RODENTS and/or RABBITS and as a laboratory animal. It is in the subfamily Mustelinae, family MUSTELIDAE. Domestic Polecat,Domestic Polecats,European Polecat,European Polecats,Ferret,Mustela putorius,Mustela putorius furo,Polecat, Domestic,Polecat, European,Polecats, Domestic,Polecats, European
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D014614 Vaccines, Synthetic Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified. Antigens, Synthetic,Chemical Vaccine,Chemical Vaccines,Immunogens, Synthetic,Molecular Vaccine,Molecular Vaccines,Recombinant Vaccine,Semisynthetic Vaccine,Semisynthetic Vaccines,Synthetic Antigen,Synthetic Vaccine,Synthetic Vaccines,Vaccines, Recombinant,Synthetic Antigens,Synthetic Immunogens,Vaccines, Chemical,Vaccines, Molecular,Vaccines, Semisynthetic,Antigen, Synthetic,Recombinant Vaccines,Vaccine, Chemical,Vaccine, Molecular,Vaccine, Recombinant,Vaccine, Semisynthetic,Vaccine, Synthetic
D014764 Viral Proteins Proteins found in any species of virus. Gene Products, Viral,Viral Gene Products,Viral Gene Proteins,Viral Protein,Protein, Viral,Proteins, Viral
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses

Related Publications

Gale E Smith, and Xiangjie Sun, and Yaohui Bai, and Ye V Liu, and Michael J Massare, and Melissa B Pearce, and Jessica A Belser, and Taronna R Maines, and Hannah M Creager, and Gregory M Glenn, and David Flyer, and Peter Pushko, and Min Z Levine, and Terrence M Tumpey
June 2008, The Journal of infectious diseases,
Gale E Smith, and Xiangjie Sun, and Yaohui Bai, and Ye V Liu, and Michael J Massare, and Melissa B Pearce, and Jessica A Belser, and Taronna R Maines, and Hannah M Creager, and Gregory M Glenn, and David Flyer, and Peter Pushko, and Min Z Levine, and Terrence M Tumpey
November 2012, Vaccine,
Gale E Smith, and Xiangjie Sun, and Yaohui Bai, and Ye V Liu, and Michael J Massare, and Melissa B Pearce, and Jessica A Belser, and Taronna R Maines, and Hannah M Creager, and Gregory M Glenn, and David Flyer, and Peter Pushko, and Min Z Levine, and Terrence M Tumpey
January 2013, Journal of virology,
Gale E Smith, and Xiangjie Sun, and Yaohui Bai, and Ye V Liu, and Michael J Massare, and Melissa B Pearce, and Jessica A Belser, and Taronna R Maines, and Hannah M Creager, and Gregory M Glenn, and David Flyer, and Peter Pushko, and Min Z Levine, and Terrence M Tumpey
March 2013, Journal of virology,
Gale E Smith, and Xiangjie Sun, and Yaohui Bai, and Ye V Liu, and Michael J Massare, and Melissa B Pearce, and Jessica A Belser, and Taronna R Maines, and Hannah M Creager, and Gregory M Glenn, and David Flyer, and Peter Pushko, and Min Z Levine, and Terrence M Tumpey
June 2009, Journal of virology,
Gale E Smith, and Xiangjie Sun, and Yaohui Bai, and Ye V Liu, and Michael J Massare, and Melissa B Pearce, and Jessica A Belser, and Taronna R Maines, and Hannah M Creager, and Gregory M Glenn, and David Flyer, and Peter Pushko, and Min Z Levine, and Terrence M Tumpey
October 2012, Virology,
Gale E Smith, and Xiangjie Sun, and Yaohui Bai, and Ye V Liu, and Michael J Massare, and Melissa B Pearce, and Jessica A Belser, and Taronna R Maines, and Hannah M Creager, and Gregory M Glenn, and David Flyer, and Peter Pushko, and Min Z Levine, and Terrence M Tumpey
October 2021, Pathogens (Basel, Switzerland),
Gale E Smith, and Xiangjie Sun, and Yaohui Bai, and Ye V Liu, and Michael J Massare, and Melissa B Pearce, and Jessica A Belser, and Taronna R Maines, and Hannah M Creager, and Gregory M Glenn, and David Flyer, and Peter Pushko, and Min Z Levine, and Terrence M Tumpey
February 2022, Viruses,
Gale E Smith, and Xiangjie Sun, and Yaohui Bai, and Ye V Liu, and Michael J Massare, and Melissa B Pearce, and Jessica A Belser, and Taronna R Maines, and Hannah M Creager, and Gregory M Glenn, and David Flyer, and Peter Pushko, and Min Z Levine, and Terrence M Tumpey
August 2014, Journal of virology,
Gale E Smith, and Xiangjie Sun, and Yaohui Bai, and Ye V Liu, and Michael J Massare, and Melissa B Pearce, and Jessica A Belser, and Taronna R Maines, and Hannah M Creager, and Gregory M Glenn, and David Flyer, and Peter Pushko, and Min Z Levine, and Terrence M Tumpey
June 2009, Future microbiology,
Copied contents to your clipboard!